JP2014521353A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521353A5
JP2014521353A5 JP2014524110A JP2014524110A JP2014521353A5 JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5 JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5
Authority
JP
Japan
Prior art keywords
vaccinia virus
present
culture
hela cells
roller bottle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014524110A
Other languages
English (en)
Japanese (ja)
Other versions
JP6243333B2 (ja
JP2014521353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/049550 external-priority patent/WO2013022764A1/en
Publication of JP2014521353A publication Critical patent/JP2014521353A/ja
Publication of JP2014521353A5 publication Critical patent/JP2014521353A5/ja
Application granted granted Critical
Publication of JP6243333B2 publication Critical patent/JP6243333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014524110A 2011-08-05 2012-08-03 ワクシニアウィルスの生成のための方法および組成物 Active JP6243333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515724P 2011-08-05 2011-08-05
US61/515,724 2011-08-05
PCT/US2012/049550 WO2013022764A1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus

Publications (3)

Publication Number Publication Date
JP2014521353A JP2014521353A (ja) 2014-08-28
JP2014521353A5 true JP2014521353A5 (enExample) 2016-10-20
JP6243333B2 JP6243333B2 (ja) 2017-12-06

Family

ID=46650950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524110A Active JP6243333B2 (ja) 2011-08-05 2012-08-03 ワクシニアウィルスの生成のための方法および組成物

Country Status (12)

Country Link
US (3) US9719105B2 (enExample)
EP (1) EP2739293B1 (enExample)
JP (1) JP6243333B2 (enExample)
KR (1) KR102022952B1 (enExample)
CN (1) CN103732236B (enExample)
AU (1) AU2012294606B2 (enExample)
BR (1) BR112014000787B1 (enExample)
CA (1) CA2841831C (enExample)
DK (1) DK2739293T3 (enExample)
ES (1) ES2813413T3 (enExample)
PL (1) PL2739293T3 (enExample)
WO (1) WO2013022764A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2017037523A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
CN106676071B (zh) * 2015-11-06 2019-07-19 天士力创世杰(天津)生物制药有限公司 HeLa-F细胞及其用途
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
CN118892540A (zh) 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
KR102684237B1 (ko) 2017-06-21 2024-07-11 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN113330111A (zh) * 2018-11-21 2021-08-31 西方溶瘤细胞有限公司 病毒的制造
SG11202106898VA (en) 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
KR102228267B1 (ko) 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021261892A1 (ko) 2020-06-22 2021-12-30 코오롱생명과학 주식회사 부유세포를 이용한 백시니아 바이러스의 대량생산방법
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
MX2023012608A (es) 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术(上海)股份有限公司 一种促进重组病毒载体向细胞外分泌的方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20260015405A1 (en) 2022-07-01 2026-01-15 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
WO2024188802A1 (en) * 2023-03-10 2024-09-19 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
EP2269618A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8030020B2 (en) * 2006-08-07 2011-10-04 Juridicial Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing live smallpox vaccine
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
WO2011017050A1 (en) 2009-07-28 2011-02-10 Corning Incorporated Synthetic microcarriers for culturing cells
WO2011032180A1 (en) * 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy

Similar Documents

Publication Publication Date Title
JP2014521353A5 (enExample)
US8778675B2 (en) Immortalized avian cell lines and use thereof
JP2019201661A5 (enExample)
JP6243333B2 (ja) ワクシニアウィルスの生成のための方法および組成物
JP2012507270A5 (enExample)
CN115785280B (zh) 重组人源纤连蛋白及其在毕赤酵母中的表达方法
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
WO2020076820A3 (en) Compositions and methods for preparing viral vectors
JP2009528843A5 (enExample)
JP2013507935A5 (enExample)
CN104087613B (zh) 基于aav‑itr的基因表达微载体及其构建方法和应用
Irie et al. Sendai virus C proteins regulate viral genome and antigenome synthesis to dictate the negative genome polarity
JP2025169249A5 (enExample)
WO2023035372A1 (zh) 一种有限自我复制mRNA分子系统、制备方法及应用
Zhang et al. Insights into leghorn male hepatocellular cells response to fowl adenovirus serotype 4 infection by transcriptome analysis
Galante et al. Identification and characterization of Orf viruses isolated from sheep and goats in Southern Italy
CN111484972A (zh) 一种从儿童包皮培养获得具备多向分化潜能和免疫调节功能间充质干细胞的方法
Bratt et al. Genetics and paragenetic phenomena of paramyxoviruses
CN112891527B (zh) 非洲猪瘟病毒i226r基因的应用
CN113583980A (zh) 一种猪繁殖与呼吸综合征突变病毒及其构建方法与应用
WO2006038742A1 (ja) 組み換えウイルスおよびその用途
Pelz et al. Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus
Saghi et al. Biochemical characterization of temperature-sensitive rabies virus mutants
JPWO2023066874A5 (enExample)
CN116162599B (zh) GSK3β在增强塞内卡病毒复制用于制备疫苗中的用途